reports
- GlobalData Department
Aratana Therapeutics Inc (PETX) - Pharmaceuticals & Healthcare - Deals...
Summary Aratana Therapeutics Inc (Aratana) is a provider of pet care solutions. The company develops, commercializing and markets biopharmaceutical products for medical condition in cats and dogs. Its pipeline portfolio consists of small molecule pharmaceuticals and large molecule biologics that aim for the treatment serious conditions in pets. Aratana offers products candidates, which include Galliprant (AT-001), for the treatment of osteoarthritis pain and inflammation; Entyce (AT-002), for a...
1 director sold
A director at Aratana Therapeutics Inc sold 75,000 shares at 6.057USD and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of a Class...
NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Aratana Therapeutics, Inc. (NASDAQ: PETX) between March 16, 2015 and February 3, 2017. You are hereby notified that Levi & Korsinsky has commenced the class action Dezi v. Aratana Therapeutics, Inc., et al. (Case No. 1:17-cv-01446) in the USDC for the Southern District of New York. To get more information go to: http://www.zlk.com/pslra/arat...
PETX INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors...
NEW YORK--(BUSINESS WIRE)-- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Aratana Therapeutics, Inc. (NASDAQ: PETX) securities between March 16, 2015 and February 3, 2017. Click here to learn about the case: http://www.wongesq.com/pslra/aratana-therapeutics. There is no cost or obligation to you. According to the complaint, throughout the Class Period Defendants made false and/or misleading...
DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadli...
STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Aratana Therapeutics, Inc. (Nasdaq:PETX) (“Aratana” or the “Company”) securities during the period between March 16, 2015 and February 3, 2017, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until April 7, 2017...
PETX INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors...
NEW YORK--(BUSINESS WIRE)-- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Aratana Therapeutics, Inc. (NASDAQ:PETX) securities between March 16, 2015 and February 3, 2017. Click here to learn about the case: http://www.wongesq.com/pslra/aratana-therapeutics. There is no cost or obligation to you. According to the complaint, throughout the Class Period Defendants made false and/or misleading ...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Has ...
NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Aratana Therapeutics, Inc. (NASDAQ:PETX) between March 16, 2015 and February 3, 2017. You are hereby notified that Levi & Korsinsky has commenced the class action Dezi v. Aratana Therapeutics, Inc., et al. (Case No. 1:17-cv-01446) in the USDC for the Southern District of New York. To get more information go to: http://www.zlk.com/pslra/arata...
INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses I...
STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Aratana Therapeutics, Inc. (Nasdaq: PETX) (“Aratana” or the “Company”) securities during the period between March 16, 2015 and February 3, 2017, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until April 7, 201...
PETX LOSS NOTICE: Rosen Law Firm Reminds Aratana Therapeutics, Inc. In...
NEW YORK--(BUSINESS WIRE)-- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aratana Therapeutics, Inc securities (NASDAQ:PETX) from March 16, 2015 through February 3, 2017, inclusive (the “Class Period”) of the important April 7, 2017 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Aratana investors under the federal securities laws. To join the Aratana class action, go to http://rosenlegal.com/cases-1049.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-fre...
INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsui...
LOS ANGELES--(BUSINESS WIRE)-- Lundin Law PC, a shareholder rights firm announces a class action lawsuit against Aratana Therapeutics, Inc. (“Aratana” or the “Company”) (Nasdaq: PETX). Investors who purchased or otherwise acquired Aratana shares between March 16, 2015 and February 3, 2017 inclusive (the “Class Period”), are encouraged to contact the firm in advance of the April 7, 2017 lead plaintiff motion deadline. To participate in this class action lawsuit, click here, or call Brian Lundin, Esquire, of Lundi...
PETX INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action...
LOS ANGELES--(BUSINESS WIRE)-- Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Aratana Therapeutics, Inc. (“Aratana” or the “Company”) (Nasdaq: PETX). Investors who purchased or otherwise acquired Aratana shares between March 16, 2015 and February 3, 2017 inclusive (the “Class Period”), are encouraged to contact the firm in advance of the April 7, 2017 lead plaintiff motion deadline. If you are a shareholder who suffered a loss during the Class Peri...
SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Arata...
LOS ANGELES--(BUSINESS WIRE)-- Goldberg Law PC announces that it is investigating Aratana Therapeutics, Inc. (“Aratana” or the “Company”) (Nasdaq: PETX) concerning possible violations of federal securities laws. If you purchased or otherwise acquired Aratana shares and would like more information regarding the investigation, we encourage you to click here, or contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your ...
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Acti...
NEW YORK--(BUSINESS WIRE)-- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Aratana Therapeutics, Inc securities (NASDAQ: PETX) from March 16, 2015 through February 3, 2017, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aratana investors under the federal securities laws. To join the Aratana class action, go to http://rosenlegal.com/cases-1049.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or e...
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Cla...
NEW YORK--(BUSINESS WIRE)-- Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Aratana Therapeutics, Inc. (NASDAQ:PETX) resulting from allegations that Aratana may have issued materially misleading business information to the investing public. On February 6, 2017, Aratana disclosed that the Center for Veterinary Medicine (“CVM”) had requested more information about Aratana’s appetite stimulation drug ENTYCE. Aratana stated that “it now anti...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of...
NEW YORK--(BUSINESS WIRE)-- Levi & Korsinsky announces it has commenced an investigation of Aratana Therapeutics, Inc. (NASDAQ:PETX) concerning possible violations of federal securities laws. On February 6, 2017, Aratana revealed that the Center for Veterinary Medicine ("CVM") had requested more information about ENTYCE, its appetite stimulation drug. Aratana informed shareholders that it “now anticipates that ENTYCE . . . will be commercially available by late 2017” and that the CVM's request was “in connection with the Comp...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.